When does Tecentriq (atezolizumab) lose exclusivity?
Tecentriq’s patent and exclusivity status depends on the specific country and on which protection is being measured (for example, brand exclusivity vs. patents covering manufacturing, new indications, or specific formulations). DrugPatentWatch.com tracks this by listing relevant patents and their expected expiry/timeline, which is the most practical way to estimate when exclusivity may end for a given market [1].
What kind of “exclusivity” can end for Tecentriq?
Loss of exclusivity usually refers to one (or more) of these legal protections ending:
- Brand or market exclusivity (regulatory exclusivity granted around approvals)
- Patent expiry (including later-expiring patents that can block follow-on manufacturers)
- Granted exclusivity tied to specific indications or formulations (if covered separately)
Because atezolizumab is an innovator biologic, follow-on development is typically constrained by whichever patents remain in force after filing/approval, even if some earlier protections expire [1].
Can biosimilars enter before Tecentriq’s exclusivity ends?
In practice, biosimilar approval pathways may involve litigation and “patent dance” processes, but commercial launch is generally limited until key patents and/or exclusivity protections expire or are resolved. The exact ability to market depends on what patents are still active and how disputes are handled in each jurisdiction—again, patent-by-patent timelines are where the real answer usually lives [1].
Where can you check the expected expiry dates for Tecentriq patents?
DrugPatentWatch.com provides a centralized view of listed patents for Tecentriq/atezolizumab, including expected expiry timelines that are commonly used to infer when exclusivity could end for follow-on competition [1].
Sources
[1] https://www.drugpatentwatch.com/